EUVIMEDEUVIMED entdecken
Multizentrische Studie

Dupilumab treatment in paediatric atopic dermatitis (2–18 years): Spanish multicentre retrospective real-world study

Helena Iznardo, Esther Roé, Asunción Vicente, Carolina Prat, Miquel Casals, Ana Martín-Santiago, Altea Esteve, Miguel Viñas, Mónica Munera-Campos, Francesca Corella, Jordi Mollet, Ignasi Figueras-Nart und 14 weitere

Clinical and Experimental Dermatology · 2024

DOI: 10.1093/ced/llae300 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Clinical and Experimental Dermatology, 2024. Verfasst von Helena Iznardo und 25 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Hospital de la Santa Creu i Sant Pau, IR SANT PAU, Universitat Autònoma de Barcelona, Barcelona, Spain. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Antibodies, Monoclonal, Humanized, Severity of Illness Index. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 49 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Moderate-to-severe atopic dermatitis (AD) can be difficult to manage in paediatric patients, and there are few licensed treatments available for this age group. Dupilumab is approved for the treatment of AD in children older than 6 months.

Objectives

To assess the effectiveness and safety of dupilumab in a real-world cohort of paediatric patients with AD in Spain.

Methods

A multicentre, retrospective real-world study on the effectiveness and safety of dupilumab in patients aged 2–18 years with moderate-to-severe AD was conducted. Demographic and clinical characteristics were analysed, and effectiveness (Eczema Area and Severity Index, Investigator’s Global Assessment, Dermatology Life Quality Index, Numerical Rating Scale itch), safety and drug survival measures were assessed. A comparison of our results with other real-world outcomes and with clinical trials was made.

Results

Data from 243 patients from 19 centres were collected, with a mean follow-up of 85 weeks. Dupilumab exhibited significant effectiveness, with marked reductions in severity scores from week 4. By week 16, 79.4% of patients achieved ≥ 75% improvement in Eczema Area and Severity Index (EASI) score (EASI 75) and 40.5% achieved ≥ 90% improvement in EASI score (EASI 90). Mean percentage reduction in EASI was 79.7%. Increasing improvements were observed until week 52, with 85.8% and 49.6% of patients achieving EASI 75 and EASI 90, respectively. Forty-three patients developed adverse events (AEs) (43 of 243, 17.7%). The most frequent AEs were ocular surface diseases (20 of 243, 8.2%), injection site reactions (8 of 243, 3.3%) and facial redness (7 of 243, 2.9%). Drug survival was high (96.9% and 93.1% after 1 and 2 years of follow-up, respectively), with only 19 patients (7.8%) interrupting treatment: 7 (2.9%) owing to AEs; 2 (0.82%) owing to secondary failure; 5 (2.1%) were lost to follow-up; and 5 (2.1%) entered remission and stopped treatment.

Conclusions

Real-world use of dupilumab in paediatric AD demonstrated sustained effectiveness, high drug survival and acceptable safety profiles. Longer-term studies are crucial for AE surveillance and understanding how to manage disease remission.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicAntibodies, Monoclonal, HumanizedSeverity of Illness IndexHumansChildRetrospective StudiesAdolescentChild, PreschoolMaleFemaleSpainTreatment OutcomeQuality of Life

Substanzen

dupilumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Dermatology, Hospital de la Santa Creu i Sant Pau, IR SANT PAU, Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Department of Dermatology, Hospital Sant Joan de Déu, Esplugues de Llobregat, Spain.
  • Department of Dermatology, Hospital Universitari de Sabadell, Sabadell, Spain.
  • Department of Dermatology, Hospital Universitari Son Espases, Palma, Spain.
  • Department of Dermatology, Consorcio Hospital Universitario General de Valencia, Valencia, Spain.
  • Department of Dermatology, Hospital Sant Antoni Abat, Vilanova I la Gertrú, Spain.

Zitieren

APA

Iznardo, H., Roé, E., Vicente, A., Prat, C., Casals, M., Martín-Santiago, A., Esteve, A., Viñas, M., Munera-Campos, M., Corella, F., Mollet, J., Figueras-Nart, I., Vila, A., Soria, X., Azón-Masoliver, A., Marqués-Martín, L., Nadal-Lladó, C., Bel, S., Pujol-Montcusí, J., …, & Baselga, E. (2024). Dupilumab treatment in paediatric atopic dermatitis (2–18 years): Spanish multicentre retrospective real-world study. Clinical and Experimental Dermatology. https://doi.org/10.1093/ced/llae300

Vancouver

Iznardo H, Roé E, Vicente A, Prat C, Casals M, Martín-Santiago A, et al. Dupilumab treatment in paediatric atopic dermatitis (2–18 years): Spanish multicentre retrospective real-world study. Clinical and Experimental Dermatology. 2024. doi:10.1093/ced/llae300

BibTeX
@article{Iznardo2024,
  author = {Iznardo, Helena and Roé, Esther and Vicente, Asunción and Prat, Carolina and Casals, Miquel and Martín-Santiago, Ana and Esteve, Altea and Viñas, Miguel and Munera-Campos, Mónica and Corella, Francesca and Mollet, Jordi and Figueras-Nart, Ignasi and Vila, Aina and Soria, Xavier and Azón-Masoliver, Antoni and Marqués-Martín, Laura and Nadal-Lladó, Cristina and Bel, Susana and Pujol-Montcusí, Josep and Bertolín-Colilla, Marta and Curto-Barredo, Laia and Melé-Ninot, Gemma and Evole, Montserrat and Berbegal, Laura and Puig, Lluís and Baselga, Eulàlia},
  title = {Dupilumab treatment in paediatric atopic dermatitis (2–18 years): Spanish multicentre retrospective real-world study},
  journal = {Clinical and Experimental Dermatology},
  year = {2024},
  doi = {10.1093/ced/llae300}
}
Kostenlos starten →